139 related articles for article (PubMed ID: 23913810)
1. The TP73 complex network: ready for clinical translation in cancer?
Soldevilla B; Millán CS; Bonilla F; Domínguez G
Genes Chromosomes Cancer; 2013 Nov; 52(11):989-1006. PubMed ID: 23913810
[TBL] [Abstract][Full Text] [Related]
2. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of the deregulated TP73 isoforms expression in cancer.
Rodríguez N; Peláez A; Barderas R; Domínguez G
Clin Transl Oncol; 2018 Jul; 20(7):827-836. PubMed ID: 29230693
[TBL] [Abstract][Full Text] [Related]
4. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1.
Domínguez G; García JM; Peña C; Silva J; García V; Martínez L; Maximiano C; Gómez ME; Rivera JA; García-Andrade C; Bonilla F
J Clin Oncol; 2006 Feb; 24(5):805-15. PubMed ID: 16380414
[TBL] [Abstract][Full Text] [Related]
5. Regulating p73 isoforms in human tumours.
Coates PJ
J Pathol; 2006 Dec; 210(4):385-9. PubMed ID: 17044134
[TBL] [Abstract][Full Text] [Related]
6. The presence of an intronic deletion in p73 and high levels of ZEB1 alter the TAp73/DeltaTAp73 ratio in colorectal carcinomas.
Domínguez G; Peña C; Silva J; García JM; García V; Rodríguez R; Cantos B; Citores MJ; España P; Bonilla F
J Pathol; 2006 Dec; 210(4):390-7. PubMed ID: 17029218
[TBL] [Abstract][Full Text] [Related]
7. TP73, an under-appreciated player in non-Hodgkin lymphoma pathogenesis and management.
Hassan HM; Dave BJ; Singh RK
Curr Mol Med; 2014 May; 14(4):432-9. PubMed ID: 24730526
[TBL] [Abstract][Full Text] [Related]
8. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations.
Faridoni-Laurens L; Tourpin S; Alsafadi S; Barrois M; Temam S; Janot F; Koscielny S; Bosq J; Bénard J; Ahomadegbe JC
Cell Cycle; 2008 Jun; 7(11):1587-96. PubMed ID: 18469517
[TBL] [Abstract][Full Text] [Related]
9. Overexpressed TP73 induces apoptosis in medulloblastoma.
Castellino RC; De Bortoli M; Lin LL; Skapura DG; Rajan JA; Adesina AM; Perlaky L; Irwin MS; Kim JY
BMC Cancer; 2007 Jul; 7():127. PubMed ID: 17626635
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
11. The role of the TP73 gene and its transcripts in neuro-oncology.
Jancalek R
Br J Neurosurg; 2014 Oct; 28(5):598-605. PubMed ID: 24742294
[TBL] [Abstract][Full Text] [Related]
12. The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site.
Orzol P; Holcakova J; Nekulova M; Nenutil R; Vojtesek B; Coates PJ
Histol Histopathol; 2015 May; 30(5):503-21. PubMed ID: 25510918
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of TP73 isoforms by 1α,25-dihydroxyvitamin D3 and survivin in human colon and breast carcinomas.
Díaz R; González-Sancho JM; Soldevilla B; Silva J; García JM; García V; Peña C; Herrera M; Gómez I; Bonilla F; Domínguez G
Genes Chromosomes Cancer; 2010 Dec; 49(12):1135-42. PubMed ID: 20842728
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of ΔTAp73 isoform levels and their target genes in colon cancer patients.
Soldevilla B; Díaz R; Silva J; Campos-Martín Y; Muñoz C; García V; García JM; Peña C; Herrera M; Rodriguez M; Gómez I; Mohamed N; Marques MM; Bonilla F; Domínguez G
Clin Cancer Res; 2011 Sep; 17(18):6029-39. PubMed ID: 21807636
[TBL] [Abstract][Full Text] [Related]
15. TP53 family members and human cancers.
Bénard J; Douc-Rasy S; Ahomadegbe JC
Hum Mutat; 2003 Mar; 21(3):182-91. PubMed ID: 12619104
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of increase in transcript levels of Tp73 DeltaEx2-3 isoforms in low-grade glioma patients.
Wager M; Guilhot J; Blanc JL; Ferrand S; Milin S; Bataille B; Lapierre F; Denis S; Chantereau T; Larsen CJ; Karayan-Tapon L
Br J Cancer; 2006 Oct; 95(8):1062-9. PubMed ID: 17047653
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism of p73-mediated regulation of hepatitis B virus core promoter/enhancer II: implications for hepatocarcinogenesis.
Buhlmann S; Racek T; Schwarz A; Schaefer S; Pützer BM
J Mol Biol; 2008 Apr; 378(1):20-30. PubMed ID: 18342333
[TBL] [Abstract][Full Text] [Related]
18. How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors.
Candi E; Agostini M; Melino G; Bernassola F
Hum Mutat; 2014 Jun; 35(6):702-14. PubMed ID: 24488880
[TBL] [Abstract][Full Text] [Related]
19. TNF-α modulates genome-wide redistribution of ΔNp63α/TAp73 and NF-κB cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer.
Si H; Lu H; Yang X; Mattox A; Jang M; Bian Y; Sano E; Viadiu H; Yan B; Yau C; Ng S; Lee SK; Romano RA; Davis S; Walker RL; Xiao W; Sun H; Wei L; Sinha S; Benz CC; Stuart JM; Meltzer PS; Van Waes C; Chen Z
Oncogene; 2016 Nov; 35(44):5781-5794. PubMed ID: 27132513
[TBL] [Abstract][Full Text] [Related]
20. TP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy.
Costanzo A; Pediconi N; Narcisi A; Guerrieri F; Belloni L; Fausti F; Botti E; Levrero M
FEBS Lett; 2014 Aug; 588(16):2590-9. PubMed ID: 24983500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
